TFG Advisers’s Bristol-Myers Squibb BMY Stock Holding History

TFG Advisers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,570	Closed	-$207K	–	201
2023 Q3	$207K	Buy	3,570 +26	+0.7%	+$1.59K	0.1%	187
2023 Q2	$227K	Buy	3,544 +94	+3%	+$6.3K	0.1%	182
2023 Q1	$239K	Buy	3,450 +90	+3%	+$6.35K	0.12%	180
2022 Q4	$242K	Buy	3,360 +56	+2%	+$4.22K	0.12%	174
2022 Q3	$235K	Buy	3,304 +19	+0.6%	+$1.38K	0.13%	166
2022 Q2	$253K	Buy	3,285 +16	+0.5%	+$1.22K	0.13%	161
2022 Q1	$239K	Buy	+3,269	New	+$219K	0.11%	182
2021 Q3	–	Sell	-3,067	Closed	-$205K	–	196
2021 Q2	$205K	Buy	+3,067	New	+$200K	0.1%	189
2021 Q1	–	Sell	-4,166	Closed	-$258K	–	190
2020 Q4	$258K	Buy	4,166 +72	+2%	+$4.43K	0.14%	157
2020 Q3	$246K	Buy	4,094 +5	+0.1%	+$301	0.14%	149
2020 Q2	$240K	Buy	4,089 +26	+0.6%	+$1.55K	0.16%	141
2020 Q1	$226K	Buy	4,063 +1,016	+33%	+$62.1K	0.18%	130
2019 Q4	$195K	Buy	+3,047	New	+$175K	0.11%	167

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

TFG Advisers's BMY Position: Q4 2023 in Review

TFG Advisers sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 3,570 shares — an estimated $207K sold.

TFG Advisers first reported a position in BMY in Q4 2019 and held it in 13 quarters. The position peaked at $258K in Q4 2020. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

TFG Advisers reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
TFG Advisers sold 3,570 Bristol-Myers Squibb shares in Q4 2023, an estimated $207K.
TFG Advisers first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 13 quarters.
TFG Advisers's Bristol-Myers Squibb position peaked at $258K in Q4 2020.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on TFG Advisers's 13F filing for Q4 2023, filed 13 Feb 2024.